相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunoproteasome Inhibitor ONX-0914 Affects Long-Term Potentiation in Murine Hippocampus
Alexander Maltsev et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2021)
Molecular and cellular dynamics of the 26S proteasome
Eri Sakata et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2021)
Microbial proteasomes as drug targets
Hao Zhang et al.
PLOS PATHOGENS (2021)
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease
Min Jae Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)
Markus Klein et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein
Tyler W. Jenkins et al.
SCIENTIFIC REPORTS (2021)
A Nut for Every Bolt: Subunit-Selective Inhibitors of the Immunoproteasome and Their Therapeutic Potential
Eva M. Huber et al.
CELLS (2021)
The proteasome and its role in the nervous system
Fulya Turker et al.
CELL CHEMICAL BIOLOGY (2021)
Proteasome Inhibitor Drugs
Lloyd D. Fricker
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders
Breanna L. Zerfas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Competitive Metabolite Profiling of Natural Products Reveals Subunit Specific Inhibitors of the 20S Proteasome
Atul Pawar et al.
ACS CENTRAL SCIENCE (2020)
LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease
Deepak Bhattarai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Plasma cell targeting to prevent antibody-mediated rejection
E. Steve Woodle et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
Michael Basler et al.
GENES AND IMMUNITY (2020)
Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides
Wenhu Zhan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Practical Review of Proteasome Pharmacology
Tiffany A. Thibaudeau et al.
PHARMACOLOGICAL REVIEWS (2019)
Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability
Ena Ladi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells
Aikaterini Skorda et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases
Jianjun Xi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits
Bo-Tao Xin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease
In Jun Yeo et al.
SCIENTIFIC REPORTS (2019)
A Sentinel in the Crosstalk Between the Nervous and Immune System: The (Immuno)-Proteasome
Fiona Limanaqi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
Andrej Besse et al.
CELL CHEMICAL BIOLOGY (2019)
Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides
Raik Artschwager et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
Michael Basler et al.
EMBO REPORTS (2018)
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenannide)
Henry W. B. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis
Christian Schmidt et al.
FRONTIERS IN IMMUNOLOGY (2018)
Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome
Michael Basler et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
An inhibitor of proteasome beta 2 sites sensitizes myeloma cells to immunoproteasome inhibitors
Sondra Downey-Kopyscinski et al.
BLOOD ADVANCES (2018)
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit
Henry W. B. Johnson et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes
Ruda de Luna Almeida Santos et al.
NATURE COMMUNICATIONS (2017)
Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome
Haissi Cui et al.
CHEMBIOCHEM (2017)
Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation
Emily S. Weyburne et al.
CELL CHEMICAL BIOLOGY (2017)
A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities
Gerjan de Bruin et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (5i) Subunit of the Immunoproteasome
Izidor Sosic et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
Susan J. Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Immunoproteasome 5i-Selective Dipeptidomimetic Inhibitors
Pradeep K. Singh et al.
CHEMMEDCHEM (2016)
A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit 5i
Eva M. Huber et al.
EMBO JOURNAL (2016)
Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes
Bo-Tao Xin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice
Esilida Sula Karreci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design
Jil Schrader et al.
SCIENCE (2016)
A Minimal -Lactone Fragment for Selective 5c or 5i Proteasome Inhibitors
Michael Groll et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Identification of a β1/β2-Specific Sulfonamide Proteasome Ligand by Crystallographic Screening
Philipp Beck et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine
Christian Dubiella et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity
Alexey Belogurov et al.
FASEB JOURNAL (2015)
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Marianne Kraus et al.
HAEMATOLOGICA (2015)
Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors
Eva M. Huber et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Marianne Kraus et al.
HAEMATOLOGICA (2015)
New C4-and C1-derivatives of furo[3,4-c] pyridine-3-ones and related compounds: Evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform
Anna Hovhannisyan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Subunit specific inhibitors of proteasomes and their potential for immunomodulation
Alexei F. Kisselev et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2014)
Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes
Gerjan de Bruin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
A FRET-based approach for identification of proteasome catalytic subunit composition
Ji Eun Park et al.
MOLECULAR BIOSYSTEMS (2014)
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome
Hao Fan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
1,2,4-Oxadiazoles Identified by Virtual Screening and their Non-Covalent Inhibition of the Human 20S Proteasome
X. Marechal et al.
CURRENT MEDICINAL CHEMISTRY (2013)
The immunoproteasome in antigen processing and other immunological functions
Michael Basler et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites
Paul P. Geurink et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib
Tamer B. Shabaneh et al.
PLOS ONE (2013)
A bright approach to the immunoproteasome: Development of LMP2/β1i-specific imaging probes
Kimberly Cornish Carmony et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice
M. Wehenkel et al.
BRITISH JOURNAL OF CANCER (2012)
Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
Eva M. Huber et al.
CELL (2012)
Activity-Based Near-Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells
Lalit Kumar Sharma et al.
CHEMBIOCHEM (2012)
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Alexei F. Kisselev et al.
CHEMISTRY & BIOLOGY (2012)
Development of proteasome inhibitors as research tools and cancer drugs
Alfred L. Goldberg
JOURNAL OF CELL BIOLOGY (2012)
Why the Structure but Not the Activity of the Immunoproteasome Subunit Low Molecular Mass Polypeptide 2 Rescues Antigen Presentation
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2012)
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors
Simone Cenci et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Molecular Model of the Human 26S Proteasome
Paula C. A. da Fonseca et al.
MOLECULAR CELL (2012)
Complete subunit architecture of the proteasome regulatory particle
Gabriel C. Lander et al.
NATURE (2012)
Mice completely lacking immunoproteasomes show major changes in antigen presentation
Eleanor Z. Kincaid et al.
NATURE IMMUNOLOGY (2012)
Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones
Wouter A. van der Linden et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2012)
New Proteasome Inhibitors in Myeloma
Panisinee Lawasut et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis
Makiko Hirai et al.
BLOOD (2011)
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib
Anne C. Mirabella et al.
CHEMISTRY & BIOLOGY (2011)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
B. C. Potts et al.
CURRENT CANCER DRUG TARGETS (2011)
Proteostenosis and plasma cell pathophysiology
Simone Cenci et al.
CURRENT OPINION IN CELL BIOLOGY (2011)
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
Christopher Blackburn et al.
BIOCHEMICAL JOURNAL (2010)
Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors
Michael Screen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Incorporation of Fluorinated Phenylalanine Generates Highly Specific Inhibitor of Proteasome's Chymotrypsin-like Sites
Paul P. Geurink et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A panel of subunit-selective activity-based proteasome probes
Martijn Verdoes et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2010)
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules
Benoit Guillaume et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
Matthew Britton et al.
CHEMISTRY & BIOLOGY (2009)
Inhibitors selective for mycobacterial versus human proteasomes
Gang Lin et al.
NATURE (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Dampening Ab responses using proteasome inhibitors following in vivo B cell activation
Paolo Cascio et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism
Michael Groll et al.
NATURE (2008)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
A cell-permeable inhilbitor and activity-based probe for the caspase-like activity of the proteasome
Paul F. van Swieten et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Regulation of CD8+ T cell development by thymus-specific proteasomes
Shigeo Murata et al.
SCIENCE (2007)
LMP2-specific inhibitors: Chemical genetic tools for proteasome biology
Yik Khuan (Abby) Ho et al.
CHEMISTRY & BIOLOGY (2007)
20S proteasome and its inhibitors: Crystallographic knowledge for drug development
Ljudmila Borissenko et al.
CHEMICAL REVIEWS (2007)
An altered T cell repertoire in MECL-1-deficient mice
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2006)
TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome
Michael Groll et al.
CHEMISTRY & BIOLOGY (2006)
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Progressively impaired proteasomal capacity during terminal plasma cell differentiation
S Cenci et al.
EMBO JOURNAL (2006)
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells
M Altun et al.
CANCER RESEARCH (2005)
Peptidyl vinyl ester derivatives: New class of selective inhibitors of proteasome trypsin-like activity
M Marastoni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
CR Berkers et al.
NATURE METHODS (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Protein degradation and protection against misfolded or damaged proteins
AL Goldberg
NATURE (2003)
The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Proteasome inhibitors: from research tools to drug candidates
AF Kisselev et al.
CHEMISTRY & BIOLOGY (2001)
Lack of proteasome active site allostery as revealed by subunit-specific inhibitors
J Myung et al.
MOLECULAR CELL (2001)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
分享论文
